Efficacy and tolerability of Hypericum extract for the ... - Livar.net

Recommendations

Info

764 S. Kasper et al. WS 5570 after recovery from a mild or moderate depressive episode. Wien. Med. Wochenschr. 157, 362–366. Kasper, S., Gastpar, M., Müller, W.E., Volz, H.P., Dienel, A., Kieser, M., Möller, H.J., 2008a. Efficacy of St. John's wort extract WS 5570 in acute treatment of mild depression: a reanalysis of data from controlled clinical trials. Eur. Arch. Psychiatr. Clin. Neurosci. 258, 59–63. Kasper, S., Volz, H.P., Möller, H.J., Dienel, A., Kieser, M., 2008b. Continuation and long-term maintenance treatment with Hypericum extract WS 5570 after recovery from an acute episode of moderate depression—a double-blind, randomized, placebo controlled long-term trial. Eur. Neuropsychopharmacol. 18, 803–813. Keller, M.B., Hirschfeld, R.M., Demyttenaere, K., Baldwin, D.S., 2002. Optimizing outcomes in depression: focus on antidepressant compliance. Int. Clin. Psychopharmacol. 17, 265–271. Kim, H.L., Streltzer, J., Goebert, D., 1999. St. John's wort for depression: a meta-analysis of well-defined clinical trials. J. Nerv. Ment. Dis. 187, 532–538. Knuppel, L., Linde, K., 2004. Adverse effects of St. John's wort: a systematic review. J. Clin. Psychiatry 65, 1470–1479. Krishnan, V., Nestler, E.J., 2008. The molecular neurobiology of depression. Nature 455, 894–902. Kumar, A., Garg, R., Prakash, A.K., 2010. Effect of St. John's wort (Hypericum perforatum) treatment on restraint stress-induced behavioral and biochemical alteration in mice. BMC Complement. Altern. Med. 10, 18. Laakmann, G., Schule, C., Baghai, T., Kieser, M., 1998. St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. Pharmacopsychiatry 31 (Suppl 1), 54–59. Lane-Brown, M.M., 2000. Photosensitivity associated with herbal preparations of St John's wort (Hypericum perforatum). Med. J. Aust. 172, 302. Lecrubier, Y., Clerc, G., Didi, R., Kieser, M., 2002. Efficacy of St. John's wort extract WS 5570 in major depression: a double-blind, placebo-controlled trial. Am. J. Psychiatry 159, 1361–1366. Lehrl, S., Woelk, H., 1993. Ergebnisse von messungen der kognitiven leistungsfähigkeit bei patienten unter der therapie mit johanniskraut. Nervenheilkunde 12, 281–284. Lemmer, W., von den Driesch, V., Klieser, E., 1999. Johanniskrautspezialextrakt WS 5572 bei leichter bis mittelschwerer depression. Wirksamkeit und vertraglichkeit von neuroplant 300 filmbletten. Fortschr. Med. 117, 143–154. Linde, K., Knuppel, L., 2005. Large-scale observational studies of Hypericum extracts in patients with depressive disorders—a systematic review. Phytomedicine 12, 148–157. Linde, K., Mulrow, C.D., 2000. St John's wort for depression. Cochrane Database Syst. Rev. CD000448. Linde, K., Ramirez, G., Mulrow, C.D., Pauls, A., Weidenhammer, W., Melchart, D., 1996. St John's wort for depression—an overview and meta-analysis of randomised clinical trials. BMJ 313, 253–258. Linde, K., Melchart, D., Mulrow, C.D., Berner, M., 2002. St John's wort and depression. JAMA 288, 447–448 author reply 448–449. Linde, K., Berner, M., Egger, M., Mulrow, C., 2005a. St John's wort for depression: meta-analysis of randomised controlled trials. Br. J. Psychiatry 186, 99–107. Linde, K., Mulrow, C.D., Berner, M., Egger, M., 2005b. St John's wort for depression (review). Cochrane Database Syst. Rev. 3, CD000448. Linde, K., Berner, M.M., Kriston, L., 2008. St John's wort for major depression. Cochrane Database Syst. Rev. CD000448. Marsh, W.L., Davies, J.A., 2002. The involvement of sodium and calcium ions in the release of amino acid neurotransmitters from mouse cortical slices elicited by hyperforin. Life Sci. 71, 2645–2655. Mennini, T., Gobbi, M., 2004. The antidepressant mechanism of Hypericum perforatum. Life Sci. 75, 1021–1027. Mills, E., Montori, V., Wu, P., Gallicano, K., Clarke, M., Guyatt, G., 2004. Interaction of St John's wort with conventional drugs: systematic review of clinical trials. BMJ 329, 27–30. Moore, L.B., Goodwin, B., Jones, S.A., Wisely, G.B., Serabjit-Singh, C.J., Willson, T.M., Collins, J.L., Kliewer, S.A., 2000. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc. Natl Acad. Sci. U. S. A. 97, 7500–7502. Moreno, R.A., Teng, C.T., Almeida, K.M., Tavares Junior, H., 2006. Hypericum perforatum versus fluoxetine in the treatment of mild to moderate depression: a randomized double-blind trial in a Brazilian sample. Rev. Bras. Psiquiatr. 28, 29–32. Moses, E.L., Mallinger, A.G., 2000. St. John's wort: three cases of possible mania induction. J. Clin. Psychopharmacol. 20, 115–117. Muller, D., Pfeil, T., von den Driesch, V., 2003. Treating depression comorbid with anxiety—results of an open, practice-oriented study with St John's wort WS 5572 and valerian extract in high doses. Phytomedicine 10 (Suppl 4), 25–30. Muller, T., Mannel, M., Murck, H., Rahlfs, V.W., 2004. Treatment of somatoform disorders with St. John's wort: a randomized, double-blind and placebo-controlled trial. Psychosom. Med. 66, 538–547. Mulsant, B.H., Ganguli, M., 1999. Epidemiology and diagnosis of depression in late life. J. Clin. Psychiatry 60 (Suppl 20), 9–15. Nierenberg, A.A., Burt, T., Matthews, J., Weiss, A.P., 1999. Mania associated with St. John's wort. Biol. Psychiatry 46, 1707–1708. Nierenberg, A.A., Quitkin, F.M., Kremer, C., Keller, M.B., Thase, M.E., 2004. Placebo-controlled continuation treatment with mirtazapine: acute pattern of response predicts relapse. Neuropsychopharmacology 229, 1012–1018. Olivier-Martin, R., 1986. Psychological factors, compliance and resistance to antidepressant treatment. Encephale 12, 197–203. Olsen, L.R., Mortensen, E.L., Bech, P., 2004. Prevalence of major depression and stress indicators in the Danish general population. Acta Psychiatr. Scand. 109, 96–103. Papakostas, G.I., Crawford, C.M., Scalia, M.J., Fava, M., 2007. Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder. A replication of findings with the use of a double-blind, placebo-controlled trial of Hypericum perforatum versus fluoxetine. Neuropsychobiology 56, 132–137. Pfrunder, A., Schiesser, M., Gerber, S., Haschke, M., Bitzer, J., Drewe, J., 2003. Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial. Br. J. Clin. Pharmacol. 56, 683–690. Philipp, M., Kohnen, R., Hiller, K.O., 1999. Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicenter study of treatment for eight weeks. BMJ 319, 1534–1538. Rahimi, R., Nikfar, S., Abdollahi, M., 2009. Efficacy and tolerability of Hypericum perforatum in major depressive disorder in comparison with selective serotonin reuptake inhibitors: a meta-analysis. Prog. Neuropsychopharmacol. Biol. Psychiatry 33, 118–127. Reichling, J., Hostanska, K., Saller, R., 2003. St. John' wort (Hypericum perforatum L.)—multicompound preparations versus single substances. Forsch. Komplementärmed. Klass. Naturheilkd 10 (Suppl 1), 28–32. Röder, C., Schaefer, M., Leucht, S., 2004. Meta-analysis of effectiveness and tolerability of treatment of mild to moderate depression with St. John's wort. Fortschr. Neurol. Psychiatr. 72, 330–343. Rychlik,R.,Siedentop,H.,vondenDriesch,V.,Kasper,S.,2001. St. John's wort extract WS 5572 in minor to moderately severe depression. Effectiveness and tolerance of 600 and 1200 mg active ingredient daily. Fortschr. Med. Orig. 119, 119–128. Schakau, D., Hiller, K.O., Schultz-Zehden, W., 1996. Nutzen/risiko-profil von johanniskrautextrakt. Psychopharmakotherapie 3, 116–122.
Efficacy and tolerability of Hypericum extract for the treatment of mild to moderate depression Schempp, C.M., Ludtke, R., Winghofer, B., Simon, J., 2000. Effect of topical application of Hypericum perforatum extract (St. John's wort) on skin sensitivity to solar simulated radiation. Photodermatol. Photoimmunol. Photomed. 16, 125–128. Schmidt, U., Sommer, H., 1993. St. John's wort extract in the ambulatory therapy of depression. Attention and reaction ability are preserved. Fortschr. Med. 111, 339–342. Schrader, E., 2000. Equivalence of St John's wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild −moderate depression. Int. Clin. Psychopharmacol. 15, 61–68. Schrader, E., Meier, B., Brattstrom, A., 1998. Hypericum treatment of mild−moderate depression in a placebo-controlled study. A prospective, double-blind, randomized, placebo-controlled, multicenter study. Hum. Psychopharmacol. 13, 163–169. Schule, C., Baghai, T., Ferrera, A., Laakmann, G., 2001. Neuroendocrine effects of Hypericum extract WS 5570 in 12 healthy male volunteers. Pharmacopsychiatry 34, S127–S133. Schulz, V., 2001. Incidence and clinical relevance of the interactions and side effects of Hypericum preparations. Phytomedicine 8, 152–160. Schulz, V., 2006. Safety of St. John's wort extract compared to synthetic antidepressants. Phytomedicine 13, 199–204. Shaper & Brummer. Esbericum capsules. Release date: 2005. Accessed on: 28 February, 2005. Available from: http://www. schaper-bruemmer.de/SUB_ICM_EN.NSF/(html)/Frameset_ load?OpenDocument&003Products_004Esbericum_002EsbericumKapseln_000EsbericumCapsules?OpenDocument&Allg- Nav_dsp?OpenForm&Kat0_root. Shelton, R.C., Keller, M.B., Gelenberg, A., Dunner, D.L., Hirschfeld, R., Thase, M.E., Russell, J., Lydiard, R.B., Crits-Cristoph, P., Gallop, R., Todd, L., Hellerstein, D., Goodnick, P., Keitner, G., Stahl, S.M., Halbreich, U., 2001. Effectiveness of St John's wort in major depression: a randomized controlled trial. JAMA 285, 1978–1986. Simbrey, K., Winterhoff, H., Butterweck, V., 2004. Extracts of St. John's wort and various constituents affect beta-adrenergic binding in rat frontal cortex. Life Sci. 74, 1027–1038. Singer, A., Wonnemann, M., Muller, W.E., 1999. Hyperforin, a major antidepressant constituent of St. John's wort, inhibits serotonin uptake by elevating free intracellular Na + . J. Pharmacol. Exp. Ther. 290, 1363–1368. Sommer, H., Harrer, G., 1994. Placebo-controlled double-blind study examining the effectiveness of an Hypericum preparation in 105 mildly depressed patients. J. Geriatr. Psychiatry Neurol. 7 (Suppl 1), S9–S11. Spielmans, G.I., 2002. St John's wort and depression. JAMA 288, 446–447 author reply 448−449. Stassen, H.H., Kuny, S., Hell, D., 1998. The speech analysis approach to determining onset of improvement under antidepressants. Eur. Neuropsychopharmacol. 8, 303–310. Stewart, J.W., Quitkin, F.M., McGrath, P.J., Amsterdam, J., Fava, M., Fawcett, J., Reimherr, F., Rosenbaum, J., Beasley, C., Roback, P., 1998. Use of pattern analysis to predict differential relapse of remitted patients with major depression during 1 year of treatment with fluoxetine or placebo. Arch. Gen. Psychiatry 55, 334–343. Szegedi, A., Muller, M.J., Anghelescu, I., Klawe, C., Kohnen, R., Benkert, O., 2003. Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. J. Clin. Psychiatry 64, 413–420. Szegedi, A., Kohnen, R., Dienel, A., Kieser, M., 2005. Acute treatment of moderate to severe depression with Hypericum extract WS 5570 (St John's wort): randomised controlled double blind non-inferiority trial versus paroxetine. BMJ 330, 503. 765 Tai-Seale, M., Croghan, T.W., Obenchain, R., 2000. Determinants of antidepressant treatment compliance: implications for policy. Med. Care Res. Rev. 57, 491–512. Taylor, L.H., Kobak, K.A., 2000. An open-label trial of St. John's wort (Hypericum perforatum) in obsessive−compulsive disorder. J. Clin. Psychiatry 61, 575–578. van Gurp, G., Meterissian, G.B., Haiek, L.N., McCusker, J., Bellavance, F., 2002. St John's wort or sertraline? Randomized controlled trial in primary care. Can. Fam. Physician 48, 905–912. Volp, A., 2002. St John's wort and depression. JAMA 288, 447 author reply 448−449. Volz, H.P., Laux, P., 2000. Potential treatment for subthreshold and mild depression: a comparison of St. John's wort extracts and fluoxetine. Compr. Psychiatry 41, 133–137. Volz, H.P., Murck, H., Kasper, S., Moller, H.J., 2002. St John's wort extract (LI 160) in somatoform disorders: results of a placebocontrolled trial. Psychopharmacology (Berl) 164, 294–300. Vorbach, E.U., Hubner, W.D., Arnoldt, K.H., 1994. Effectiveness and tolerance of the Hypericum extract LI 160 in comparison with imipramine: randomized double-blind study with 135 outpatients. J. Geriatr. Psychiatry Neurol. 7 (Suppl 1), S19–S23. Wagner, H., Bladt, S., 1994. Pharmaceutical quality of Hypericum extracts. J. Geriatr. Psychiatry Neurol. 7 (Suppl 1), S65–S68. Westerhoff, K., Kaunzinger, A., Wurglics, M., Dressman, J., Schubert-Zsilavecz, M., 2002. Biorelevant dissolution testing of St John's wort products. J. Pharm. Pharmacol. 54, 1615–1621. Wheatley, D., 1997. LI 160, an extract of St. John's wort, versus amitriptyline in mildly to moderately depressed outpatients—a controlled 6-week clinical trial. Pharmacopsychiatry 30 (Suppl 2), 77–80. Wheatley, D., 2002. St John's wort and depression. JAMA 288, 446 author reply 448–449. Whiskey, E., Werneke, U., Taylor, D., 2001. A systematic review and meta-analysis of Hypericum perforatum in depression: a comprehensive clinical review. Int. Clin. Psychopharmacol. 16, 239–252. Whitten, D.L., Myers, S.P., Hawrelak, J.A., Wohlmuth, H., 2006. The effect of St John's wort extracts on CYP3A: a systematic review of prospective clinical trials. Br. J. Clin. Pharmacol. 62, 512–526. Wilhelm, K., Mitchell, P., Slade, T., Brownhill, S., Andrews, G., 2003. Prevalence and correlates of DSM-IV major depression in an Australian national survey. J. Affect. Disord. 75, 155–162. Witte, B., Harrer, G., Kaptan, T., Podzuweit, H., Schmidt, U., 1995. Treatment of depressive symptoms with a high concentration Hypericum preparation. A multicenter placebo-controlled double-blind study. Fortschr. Med. 113, 404–408. Woelk, H., 2000. Comparison of St John's wort and imipramine for treating depression: randomised controlled trial. BMJ 321, 536–539. Woelk, H., Burkard, G., Grunwald, J., 1994. Benefits and risks of the Hypericum extract LI 160: drug monitoring study with 3250 patients. J. Geriatr. Psychiatry Neurol. 7 (Suppl 1), S34–S38. Yoshitake, T., Iizuka, R., Yoshitake, S., Weikop, P., Müller, W.E., Ogren, S.O., Kehr, J., 2004. Hypericum perforatum L (St John's wort) preferentially increases extracellular dopamine levels in the rat prefrontal cortex. Br. J. Pharmacol. 142, 414–418. Zeller, K., 2000. A convincing safety profile of St. John's wort extract (Laif 600) shown in a large post marketing surveillance. Phytomedicine 7, 107. Zhou, S.F., Lai, X., 2008. An update on clinical drug interactions with the herbal antidepressant St. John's wort. Curr. Drug Metab. 5, 394–409.
Page 1 and 2: European Neuropsychopharmacology (2
Page 3 and 4: Efficacy and tolerability of Hyperi
Page 5 and 6: Placebo as comparator in long-term
Page 17: Efficacy and tolerability of Hyperi

Efficacy and tolerability of Hypericum extract for the ... - Livar.net

Create successful ePaper yourself

Delete template?

Save as template?